Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma

Journal of Clinical Oncology

Volumn 34, Issue 34, 2016, Pages 4102-4109

  Daud, Adil I ^a   Wolchok, Jedd D ^e   Robert, Caroline ^o   Hwu, Wen Jen ^f   Weber, Jeffrey S ^h   Ribas, Antoni ^b   Hodi, F Stephen ^j   Joshua, Anthony M ^p   Kefford, Richard ^q,r,s   Hersey, Peter ^s   Joseph, Richard ⁱ   Gangadhar, Tara C ^k   Dronca, Roxana ^m   Patnaik, Amita ^g   Zarour, Hassane ^l   Roach, Charlotte ^d   Toland, Grant ^d   Lunceford, Jared K ⁿ   Li, Xiaoyun Nicole ⁿ   Emancipator, Kenneth ⁿ   Dolled Filhart, Marisa ⁿ   Kang, S Peter ⁿ   Ebbinghaus, Scot ⁿ   Hamid, Omid ^c   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Angeles Clinic and Research Institute   (United States)

^d AGILENT TECHNOLOGIES   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g South Texas Accelerated Research Therapeutics   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ MAYO CLINIC   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l UNIVERSITY OF PITTSBURGH   (United States)

^m MAYO CLINIC   (United States)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

^o UNIVERSITÉ PARIS SACLAY   (France)

^p PRINCESS MARGARET HOSPITAL   (Canada)

^q WESTMEAD HOSPITAL   (Australia)

^r MACQUARIE UNIVERSITY   (Australia)

^s UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SKIN BIOPSY; SYSTEMIC THERAPY; TUMOR BIOPSY; TUMOR VOLUME; ADOLESCENT; CLINICAL TRIAL; DRUG ADMINISTRATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84995890821     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.2477     Document Type: Article

References (39)

1. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331:1565-1570, 2011
2. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252-264, 2012
3. Chen DS, Mellman I: Oncology meets immunology: The cancer-immunity cycle. Immunity 39:1-10, 2013
4. Page DB, Postow MA, Callahan MK, et al: Immune modulation in cancer with antibodies. Annu Rev Med 65:185-202, 2014
5. Krummel MF, Allison JP: Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The Journal of Experimental Medicine. 1995. 182: 459-465. J Immunol 187:3459-3465, 2011
6. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
7. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
8. Ishida Y, Agata Y, Shibahara K, et al: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887-3895, 1992
9. Agata Y, Kawasaki A, Nishimura H, et al: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765-772, 1996
10. Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-1034, 2000
11. Liang SC, Latchman YE, Buhlmann JE, et al: Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 33:2706-2716, 2003
12. Brahmer JR, Drake CG, Wollner I, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175, 2010
13. Taube JM, Anders RA, Young GD, et al: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra37, 2012
14. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
15. Herbst RS, Soria JC, Kowanetz M, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-567, 2014
16. Hamid O, Robert C, Daud A, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-144, 2013
17. Robert C, Ribas A, Wolchok JD, et al: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109-1117, 2014
18. Robert C, Joshua AM, Weber JS, et al: Pembrolizumab (pembro; MK-3475) for advanced melanoma (MEL): Randomized comparison of two dosing schedules. Ann Oncol 25, 2014 (suppl 4; abstr LBA34)
19. Plimack ER, Gupta S, Bellmunt J, et al: A phase 1b study of pembrolizumab (pembro; MK-3475) in patients with advanced urothelial cancer. Ann Oncol 25, 2014 (suppl 4; abstr LBA23)
20. Muro K, Chung HC, Shankaran V, et al: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, openlabel, phase 1b trial. Lancet Oncol 17:717-726, 2016
21. Chow LQM, Haddad R, Gupta S, et al: Antitumor activity of pembrolizumab in biomarkerunselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34:3838-3845, 2016
22. Nanda R, Chow LQ, Dees EC, et al: Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol 34:2460-2467, 2015
23. Armand P, Shipp MA, Ribrag V, et al: Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 34:3733-3739, 2016
24. Ribas A, Hamid O, Daud A, et al: Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:1600-1609, 2016
25. Ribas A, Puzanov I, Dummer R, et al: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 16:908-918, 2015
26. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-2532, 2015
27. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018-2028, 2015
28. Daud AI, Hamid O, Antoni-Ribas F, et al: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma (MEL): Correlation of tumor PD-L1 expression with outcome. Cancer Res 74 (suppl 19; abstr CT104), 2014
29. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
30. Wolchok JD, Hoos A, O'Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15:7412-7420, 2009
31. Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998
32. Miettinen O, Nurminen M: Comparative analysis of two rates. Stat Med 4:213-226, 1985
33. Robert C, Long GV, Brady B, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320-330, 2015
34. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23-34, 2015
35. Kerr KM, Tsao MS, Nicholson AG, et al: Programmed death-ligand 1 immunohistochemistry in lung cancer: In what state is this art? J Thorac Oncol 10:985-989, 2015
36. Tumeh PC, Harview CL, Yearley JH, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568-571, 2014
37. Jilaveanu LB, Shuch B, Zito CR, et al: PD-L1 expression in clear cell renal cell carcinoma: An analysis of nephrectomy and sites of metastases. J Cancer 5:166-172, 2014
38. Madore J, Vilain RE, Menzies AM, et al: PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 28:245-253, 2015
39. Liu J, Hamrouni A, Wolowiec D, et al: Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110:296-304, 2007